Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 500

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1C
Chunk 500
---
 Equity 
    $2,506,290  
    $5,951,736 

The
accompanying notes are an integral part of these consolidated financial statements.

F-2

Shuttle
Pharmaceuticals Holdings, Inc.

Consolidated
Statements of Operations

    2024  
    2023 

    Years Ended December 31, 

    2024  
    2023 

    Revenue 
    $—  
     — 

    Operating expenses 

    Research and development, net of contract expense reimbursements 
     3,618,796  
     3,517,093 
  
    General and administrative 
     1,392,709  
     1,046,854 
  
    Legal and professional 
     2,684,665  
     1,328,435 
  
    Total operating expenses 
     7,696,170  
     5,892,382 

    Net loss from operations 
     (7,696,170) 
     (5,892,382)

    Other income (expense) 

    Interest expense - related parties 
     (8,692) 
     (6,825)
  
    Interest expense 
     (1,198,738) 
     (2,484,193)
  
    Interest income 
     38,138  
     79,117 
  
    Convertible notes finance fee 
     (152,726) 
     (104,245)
  
    Change in fair value of derivative liabilities 
     555,789  
     2,216,488 
  
    Change in fair value of convertible notes 
     122,553  
     — 
  
    Gain on sale of marketable securities 
     28,550  
     4,970 
  
    Change in fair value of marketable securities 
     — 
     71,568 
  
    Loss on settlement of convertible debt 
     (833,501) 
     (477,221)
  
    Total other income (expense) 
     (1,448,627) 
     (700,341)

    Net loss 
     (9,144,797) 
     (6,592,723)

    Weighted average common shares outstanding - basic 
     2,870,120